Lung-targeted drugs

• US 8,318,700 B2
• Filed: 01/18/2012
• Issued: 11/27/2012
• Est. Priority Date: 12/16/2004
• Status: Active Grant

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Hostetler, Karl Y., Beadle, James R.
• Primary Examiner(s): Jiang, Shaojia Anna
• Assistant Examiner(s): Lau, Jonathan S
• Application Number:
  US13/353,034
• Publication Number:
  US 20120122818A1
• Time in Patent Office: 314 Days
• Field of Search: 514/75, 514/81, 514/99, 514/141, 514/148, 544/277, 549/218
• US Class Current: 514/75
• CPC Class Codes: A61K 47/543 Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07F 9/6512 having the nitrogen atoms in positions 1 and 3
• CPC Class Codes: C07F 9/65616 containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
• CPC Class Codes: C07H 19/10 with the saccharide radical esterified by phosphoric or polyphosphoric acids

Abstract

Methods and compositions are provided for treating lung diseases, including but not limited to infections and small cell and non-small cell lung cancer, by conjugating a drug of interest to glycerol ethers or glycerol phosphate ethers.

Claims

1. A compound having the structure

2. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.

3. A compound having the structure

4. A pharmaceutical composition comprising the compound according to claim 3 and a pharmaceutically acceptable carrier.